Kumar Vijender, Bhat Zulfiqar Ali, Kumar Dinesh, Khan N A, Chashoo I A
Department of Pharmaceutical Sciences, University of Kashmir, Srinagar-190006, India.
Asian Pac J Trop Biomed. 2012 Aug;2(8):627-30. doi: 10.1016/S2221-1691(12)60109-9.
To evaluate anti-inflammatory potential of leaf extract of Skimmia anquetilia by in-vitro and in-vivo anti-inflammatory models.
Acute toxicity study was carried out to determine the toxicity level of different extract using acute toxic class method as described in Organization of Economic Co-operation and Development Guidelines No.423. Carrageenan (1% w/w) was administered and inflammation was induced in rat paw. The leaf extracts of Skimmia anquetilia were evaluated for anti-inflammatory activity by in-vitro human red blood cell (HRBC) membrane stabilization method and in-vivo carrangeenan-induced rat paw edema method.
The in-vitro membrane stabilizing test showed petroleum ether (PE), chloroform (CE), ethyl acetate (EE), methanol (ME) and aqueous extracts (AE) showed 49.44%, 59.39%, 60.15%, 68.40% and 52.18 % protection, respectively as compared to control groups. The in-vivo results of CE, EE and ME showed 58.20%, 60.17% and 67.53% inhibition of inflammation after 6h administration of test drugs in albino rats. The potency of the leaf extracts of Skimmia anquetilia were compared with standard diclofenac (10 mg/kg) which showed 74.18% protection in in-vitro HRBC membrane stabilization test and 71.64% inhibition in in-vivo carrangeenan-induced rat paw edema model. The ME showed a dose dependent significant (P< 0.01) anti-inflammatory activity in human red blood cell membrane stabilization test and reduction of edema in carrageenan induced rat paw edema.
The present investigation has confirmed the anti-inflammatory activity of Skimmia anquetilia due to presence of bioactive phytoconstitutes for the first time and provide the pharmacological evidence in favor of traditional claim of Skimmia anquetilia as an anti- inflammatory agent.
通过体外和体内抗炎模型评估印度茵芋叶提取物的抗炎潜力。
按照经济合作与发展组织第423号指南所述的急性毒性分级法进行急性毒性研究，以确定不同提取物的毒性水平。给予角叉菜胶（1% w/w）诱导大鼠爪部炎症。通过体外人红细胞（HRBC）膜稳定法和体内角叉菜胶诱导的大鼠爪部水肿法评估印度茵芋叶提取物的抗炎活性。
体外膜稳定试验显示，与对照组相比，石油醚（PE）、氯仿（CE）、乙酸乙酯（EE）、甲醇（ME）和水提取物（AE）的保护率分别为49.44%、59.39%、60.15%、68.40%和52.18%。在白化大鼠中给予受试药物6小时后，CE、EE和ME的体内结果显示炎症抑制率分别为58.20%、60.17%和67.53%。将印度茵芋叶提取物的效力与标准双氯芬酸（10 mg/kg）进行比较，标准双氯芬酸在体外HRBC膜稳定试验中的保护率为74.18%，在体内角叉菜胶诱导的大鼠爪部水肿模型中的抑制率为71.64%。ME在人红细胞膜稳定试验中显示出剂量依赖性的显著（P<0.01）抗炎活性，并可减轻角叉菜胶诱导的大鼠爪部水肿。
本研究首次证实了印度茵芋由于存在生物活性植物成分而具有抗炎活性，并为印度茵芋作为抗炎剂的传统说法提供了药理学证据。
